{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.03","upperLimit":"24.99","value":"17.00"},{"groupId":"OG001","lowerLimit":"4.50","upperLimit":"15.19","value":"6.28"},{"comment":"Not calculated due to insufficient number of events","groupId":"OG002","lowerLimit":"1.58","upperLimit":"NA","value":"14.70"},{"comment":"Not calculated due to insufficient number of events","groupId":"OG003","lowerLimit":"9.73","upperLimit":"NA","value":"14.56"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from randomization to death from any cause, and was calculated using date of first dose and date of death, or date of last follow-up for censored subjects.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were given oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG000","title":"Stable Disease (SD) Cohort: Oral Azacitidine"},{"description":"Participants were given oral azacitidine 100 mg, 150mg, or 200mg tablets BID on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG001","title":"Progressive Disease (PD) Cohort: Oral Azacitidine"},{"description":"Participants received 100 mg oral azacitidine (AZA) tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab (Durva) 1500 mg by intravenous infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG002","title":"Stable Disease Cohort: Oral Azacitidine and Durvalumab"},{"description":"Participants received 100 mg oral azacitidine tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab 1500 mg by intravenous infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG003","title":"Progressive Disease Cohort: Oral Azacitidine and Durvalumab"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all enrolled participants who received at least one dose of IP.","reportingStatus":"POSTED","timeFrame":"From first dose till death due to any cause (Up to 91 months)","title":"Kaplan-Meier Estimate of Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}